345 related articles for article (PubMed ID: 26094596)
21. Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells.
Naito Y; Sakamoto S; Kojima T; Homma M; Tanaka M; Matsui H
SLAS Discov; 2023 Oct; 28(7):344-349. PubMed ID: 37369311
[TBL] [Abstract][Full Text] [Related]
22. Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate.
Migdalska-Richards A; Ko WKD; Li Q; Bezard E; Schapira AHV
Synapse; 2017 Jul; 71(7):. PubMed ID: 28295625
[TBL] [Abstract][Full Text] [Related]
23. Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients.
Parnetti L; Paciotti S; Eusebi P; Dardis A; Zampieri S; Chiasserini D; Tasegian A; Tambasco N; Bembi B; Calabresi P; Beccari T
Mov Disord; 2017 Oct; 32(10):1423-1431. PubMed ID: 28843015
[TBL] [Abstract][Full Text] [Related]
24. Ambroxol modulates 6-Hydroxydopamine-induced temporal reduction in Glucocerebrosidase (GCase) enzymatic activity and Parkinson's disease symptoms.
Mishra A; Chandravanshi LP; Trigun SK; Krishnamurthy S
Biochem Pharmacol; 2018 Sep; 155():479-493. PubMed ID: 30040928
[TBL] [Abstract][Full Text] [Related]
25. Molecular mechanisms of the ambroxol action in Gaucher disease and GBA1 mutation-associated Parkinson disease.
Cyske Z; Gaffke L; Rintz E; Wiśniewska K; Węgrzyn G; Pierzynowska K
Neurochem Int; 2024 May; 178():105774. PubMed ID: 38797393
[TBL] [Abstract][Full Text] [Related]
26. The LIMP-2/SCARB2 binding motif on acid β-glucosidase: basic and applied implications for Gaucher disease and associated neurodegenerative diseases.
Liou B; Haffey WD; Greis KD; Grabowski GA
J Biol Chem; 2014 Oct; 289(43):30063-74. PubMed ID: 25202012
[TBL] [Abstract][Full Text] [Related]
27. Reduced glucocerebrosidase activity in monocytes from patients with Parkinson's disease.
Atashrazm F; Hammond D; Perera G; Dobson-Stone C; Mueller N; Pickford R; Kim WS; Kwok JB; Lewis SJG; Halliday GM; Dzamko N
Sci Rep; 2018 Oct; 8(1):15446. PubMed ID: 30337601
[TBL] [Abstract][Full Text] [Related]
28. Dissociation of glucocerebrosidase dimer in solution by its co-factor, saposin C.
Gruschus JM; Jiang Z; Yap TL; Hill SA; Grishaev A; Piszczek G; Sidransky E; Lee JC
Biochem Biophys Res Commun; 2015 Feb; 457(4):561-6. PubMed ID: 25600808
[TBL] [Abstract][Full Text] [Related]
29. Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease.
Murphy KE; Gysbers AM; Abbott SK; Tayebi N; Kim WS; Sidransky E; Cooper A; Garner B; Halliday GM
Brain; 2014 Mar; 137(Pt 3):834-48. PubMed ID: 24477431
[TBL] [Abstract][Full Text] [Related]
30. Lysosome sorting of β-glucocerebrosidase by LIMP-2 is targeted by the mannose 6-phosphate receptor.
Zhao Y; Ren J; Padilla-Parra S; Fry EE; Stuart DI
Nat Commun; 2014 Jul; 5():4321. PubMed ID: 25027712
[TBL] [Abstract][Full Text] [Related]
31. Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models.
Sanchez-Martinez A; Beavan M; Gegg ME; Chau KY; Whitworth AJ; Schapira AH
Sci Rep; 2016 Aug; 6():31380. PubMed ID: 27539639
[TBL] [Abstract][Full Text] [Related]
32. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
33. Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease.
Menozzi E; Schapira AHV
CNS Drugs; 2020 Sep; 34(9):915-923. PubMed ID: 32607746
[TBL] [Abstract][Full Text] [Related]
34. GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.
Johnson PH; Weinreb NJ; Cloyd JC; Tuite PJ; Kartha RV
Mol Genet Metab; 2020 Feb; 129(2):35-46. PubMed ID: 31761523
[TBL] [Abstract][Full Text] [Related]
35. Glucocerebrosidase Defects as a Major Risk Factor for Parkinson's Disease.
Avenali M; Blandini F; Cerri S
Front Aging Neurosci; 2020; 12():97. PubMed ID: 32372943
[TBL] [Abstract][Full Text] [Related]
36. Glucocerebrosidase and Parkinson disease: Recent advances.
Schapira AH
Mol Cell Neurosci; 2015 May; 66(Pt A):37-42. PubMed ID: 25802027
[TBL] [Abstract][Full Text] [Related]
37. N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease.
García-Sanz P; Orgaz L; Bueno-Gil G; Espadas I; Rodríguez-Traver E; Kulisevsky J; Gutierrez A; Dávila JC; González-Polo RA; Fuentes JM; Mir P; Vicario C; Moratalla R
Mov Disord; 2017 Oct; 32(10):1409-1422. PubMed ID: 28779532
[TBL] [Abstract][Full Text] [Related]
38. Role of LIMP-2 in the intracellular trafficking of β-glucosidase in different human cellular models.
Malini E; Zampieri S; Deganuto M; Romanello M; Sechi A; Bembi B; Dardis A
FASEB J; 2015 Sep; 29(9):3839-52. PubMed ID: 26018676
[TBL] [Abstract][Full Text] [Related]
39. Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease.
Ron I; Rapaport D; Horowitz M
Hum Mol Genet; 2010 Oct; 19(19):3771-81. PubMed ID: 20643691
[TBL] [Abstract][Full Text] [Related]
40. Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies.
Chiasserini D; Paciotti S; Eusebi P; Persichetti E; Tasegian A; Kurzawa-Akanbi M; Chinnery PF; Morris CM; Calabresi P; Parnetti L; Beccari T
Mol Neurodegener; 2015 Mar; 10():15. PubMed ID: 25881142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
